BERTOCCI DEREK A 4
4 · Guardant Health, Inc. · Filed May 26, 2020
Insider Transaction Report
Form 4
BERTOCCI DEREK A
Chief Financial Officer
Transactions
- Exercise/Conversion
COMMON STOCK
2020-05-22$3.63/sh+7,685$27,897→ 69,872 total - Sale
COMMON STOCK
2020-05-22$95.38/sh−1,118$106,632→ 70,291 total - Sale
COMMON STOCK
2020-05-22$96.77/sh−6,960$673,542→ 63,331 total - Exercise/Conversion
STOCK OPTION (RIGHT TO BUY)
2020-05-22−7,685→ 7,686 totalExercise: $3.63Exp: 2026-07-26→ COMMON STOCK (7,685 underlying) - Exercise/Conversion
STOCK OPTION (RIGHT TO BUY)
2020-05-22−1,537→ 20,751 totalExercise: $8.80Exp: 2028-08-21→ COMMON STOCK (1,537 underlying) - Exercise/Conversion
COMMON STOCK
2020-05-22$8.80/sh+1,537$13,526→ 71,409 total - Sale
COMMON STOCK
2020-05-22$97.00/sh−1,144$110,972→ 62,187 total
Footnotes (6)
- [F1]These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.87 to $95.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.97 to $96.955, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $96.97 to $97.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The stock option vests and becomes exercisable as to 25% of the options on July 18, 2017, thereafter vests in equal monthly installments over 36 months.
- [F6]The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018.